Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ZIOPHARM Announces Approval of IND for ZIO-101
Phase I trial in cancer to begin this month
View HTML
Toggle Summary ZIOPHARM Initiates Collaborative Research Agreement with Southern Research Institute
Option on Novel IPM Analogs
View HTML
Toggle Summary ZIOPHARM and The University of Texas M.D. Anderson Cancer Center Present Data on ZIO-102 at American Society of Hematology Second Organic Arsenic View HTML
Toggle Summary ZIOPHARM Secures Exclusive License to IPM
Phase I Trial Ongoing
View HTML
Toggle Summary ZIOPHARM Receives ZIO-101 Notice of Patent Allowance Novel Class of Organic Arsenicals Targeted to Enter Clinic in 2005 View HTML
Toggle Summary ZIOPHARM Presents Data on New Class of Arsenic Compounds at International Leukemia Meeting View HTML
Toggle Summary ZIOPHARM Licenses A New Class Of Arsenic Drugs From M. D. Anderson Cancer Center Smart New Chemistry for Cancer Treatment View HTML
Toggle Summary ZIOPHARM Forms Board of Directors
ZIOPHARM Forms Board of Directors NEW HAVEN, CT SEPT 15 - Privately held ZIOPHARM, Inc., a developer of cancer drugs, announced it named eight individuals with diverse backgrounds in medicine, pharmaceutical and biotechnology management, legal and government affairs, and finance and communications
View HTML
Toggle Summary ZIOPHARM Forms Medical Advisory Board View HTML
Toggle Summary ZIOPHARM Fills Three New Senior Management Posts View HTML